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Introduction: Matrix metalloproteinase-8 (MMP-8; neutrophil collagenase) is an important regulator of innate
immunity that has oncosuppressive actions in numerous tumor types.
Methods: We have intercrossed Mmp8-null mice with the Polyoma virus middle T oncogene-driven (MMTV-PyMT)
mouse model of mammary cancer to explore the effects of loss of MMP-8 on the incidence and progression of
mammary carcinomas.
Results: In this aggressive mouse model of breast cancer, loss of MMP-8 accelerated tumor onset even further, such that
90% of MMTV-PyMT; Mmp8-null female mice were tumor-bearing at the time of weaning. Throughout the 14 weeks of
the model, tumor burden increased in homozygous Mmp8-null mice compared to Mmp8-wild-type and -heterozygote
animals. Likewise, lung metastasis dramatically increased in the MMTV-PyMT; Mmp8-null mice. Immunohistochemistry
revealed that tumors in wild-type, Mmp8-heterozygotes and -null animals had similar vascular density at 8 weeks, but at
10 weeks Mmp8-wild-type tumors had a lower vascularity than their heterozygote and null counterparts. No differences in
macrophage infiltration were apparent throughout primary tumor development, though at 10 weeks a drop in neutrophil
infiltrates was observed in Mmp8-wild-type tumors. Using quantitative real-time RT-PCR, we tracked the expression of the
entire Mmp and Timp gene families, observing a significant decrease in Mmp3 expression in Mmp8-null tumors compared
to wild-type and heterozygotes throughout the time course of the model, which was confirmed at the protein level.
Conclusions: These findings provide novel insight into the suppressive action of MMP-8 on mammary tumorigenesis and
metastasis, and indicate that the loss of MMP-8 likely has pleiotropic effects on innate immunity and angiogenesis that
are reflected in changes in the protease web.Introduction
The matrix metalloproteinase (MMP) family of secreted
Zn-dependent endopeptidases play important roles in
physiological processes and disease states via their ef-
fects on the structure and content of the extracellular
environment. In cancer they have been identified as key
regulators of cell proliferation, apoptosis, migration, inva-
sion, angiogenesis and the immune system [1]. In humans,
the MMP family consists of 24 enzymes that can be* Correspondence: juliedecock80@gmail.com; dylan.edwards@uea.ac.uk
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unless otherwise stated.categorized based on their structural similarities and
substrate specificities into collagenases, gelatinases,
matrilysins, stromelysins, membrane-bound MMPs and
others. It was originally thought that MMPs acted en
masse to promote tumorigenesis and progression via extra-
cellular matrix (ECM) degradation that permitted cancer
cell invasion, which led to the development of broad-
spectrum synthetic inhibitors as anti-cancer therapies.
However, these agents subsequently proved disappoint-
ing in the clinic, contributing to the recognition that
the roles of the MMPs are much more complex than
originally believed [2,3]. Recent evidence has demon-
strated that MMP family members exhibit both pro- and
anti-tumorigenic/metastatic functions and thus their in-
hibition can have adverse consequences [4,5]. One of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumorigenic and anti-metastatic functions was MMP-8.
MMP-8, otherwise known as neutrophil collagenase
thanks to its abundant expression in neutrophil granules,
can be expressed by a wide variety of cell types including
epithelial cells, fibroblasts, endothelial cells, macrophages
and neutrophils [6]. We, and others, have demonstrated
that MMP-8 exerts tumorigenic and/or metastasis sup-
pressive roles. Human correlation studies have shown
that positive MMP-8 expression is linked to a lower risk of
cancer incidence and metastasis, and to prolonged disease-
free and overall survival [7-12]. Using a carcinogen-induced
skin tumorigenesis mouse model, Balbin et al. reported in
2003 that the absence of MMP-8 dramatically increased the
incidence of skin papillomas in male Mmp8-null mice,
while a similar observation for tongue squamous car-
cinomas was made by Korpi et al. a few years later
[10,13]. Xenograft models with breast cancer and melan-
oma cells have also demonstrated the anti-metastatic abil-
ity of MMP-8 [9,14,15]. Analysis of a pair of breast tumor
cell lines, originating from the same breast tumor but with
opposite metastatic capabilities, revealed increased expres-
sion of MMP-8 in the non-metastatic cell line and corre-
sponding xenograft [16]. Furthermore, downregulation of
MMP-8 in the non-metastatic cell line led to increased in-
vasion through Matrigel [16] and enhanced lung metasta-
sis [17]. Enhanced expression of MMP-8 by melanoma
cells was found to decrease their invasion and migration
by enhancing their adhesion to the ECM [9]. A recent
breast cancer xenograft study has provided insight into po-
tential molecular mechanisms behind this anti-metastatic
behavior, indicating that MMP-8 cleavage of decorin from
the ECM leads to downregulation of active transforming
growth factor beta (TGF-β) and consequent suppression of
miR-21 expression [15]. Furthermore, MMP-8 has a range
of extracellular substrates including cytokines, chemokines,
growth factors, ECM proteins, proteases and protease
inhibitors [6,17]. There is accumulating evidence that
MMP-8 regulates the innate immune system in vivo via the
cleavage of chemokines and cytokines. MMP-8 has been
implicated in the acute immune response in a number
of experimental models of inflammatory diseases where
it can either act to promote or hinder the inflammatory
response [18]. We recently reported that enhanced pro-
duction of MMP-8 by breast cancer cells induced the ex-
pression of the proinflammatory mediators interleukin-6
(IL-6) and IL-8 [19]. Thus, MMP-8 may participate in and
orchestrate multiple events in the tumor microenvironment
during the stages of tumor progression.
In the present study, we have explored the effects of con-
stitutional loss of MMP-8 on mammary oncogenesis and
metastasis in the mouse mammary tumor virus-Polyoma
virus middle T-antigen (MMTV-PyMT) mouse, which is a
rapid and robust model of human luminal breast cancer[20]. These mice develop pre-malignant epithelial hyper-
plasia as early as 4 weeks, which progresses to overt carcin-
oma by 12 weeks at which time essentially all of the mice
show metastasis to the lung and lymph nodes [21-23]. This
work represents the first study exploring the role of MMP-
8 in a spontaneous cancer mouse model. We show here
that in the absence of MMP-8, the oncogenic program
in MMTV-PyMT mice is further accelerated as tumor
latency is decreased and the resulting lesions grow larger,
generating increased numbers of lung macrometastases.
Increased malignancy was also evident from changes in
tumor vascularity and immune cell infiltration in Mmp8-
deficient mice that became apparent at later stages of the
model. We also found that the complete absence of MMP-
8 had repercussions for other MMP family members, with
MMP-3 in particular showing reduced expression through-
out the time course of the model. This suggests that the
position of MMP-8 in the interconnected ‘protease web’
may have extensive downstream consequences [24].
Together these findings confirm the anti-tumorigenic
and anti-metastatic functions of MMP-8 in a spontan-
eous mouse mammary cancer model and highlight its
impact on multiple components, including angiogenesis
and inflammatory cell involvement.
Materials and methods
Mice and genotyping
The Mmp8-null mice were previously described [9,13].
MMTV-PyMT mice (Charles River Laboratories, Margate,
UK) were on the FVB/n genetic background and Mmp8-
null mice were backcrossed onto the FVB/n genetic back-
ground for more than eight generations. Both mouse strains
were intercrossed and male MMTV-PyMT offspring were
used to establish sibling cohorts of MMTV-PyMT; Mmp8-
wild-type (WT), MMTV-PyMT; Mmp8-heterozygote (HET)
and MMTV-PyMT; Mmp8-null (KO) females. Mouse
husbandry and animal experiments were conducted
under Home Office project license PPL 80/2288 in accord-
ance with the Animals (Scientific Procedures) Act 1986,
with the approval of the University of East Anglia Ethics
Review Committee.
Genotyping of ear snips was performed using PyMT-3p
primer 5′- CGG CGG AGC GAG GAA CTG AGG AGA
G −3′ and PyMT-4 m primer 5′-TCA GAA GAC TCG
GCA GTC TTA GGC G – 3′ for detection of the PyMT
transgene; and Mmp8-Anchor primer 5′- AGC CCT TAA
ACC GCT AAG GA – 3′, Mmp8-WT primer 5′- TCG
TCT CAA GAG GTA GGC TCA– 3′ and Mmp8-Neo
primer 5′- GCC AGA GGC CAC TTG TGT AG −3′ for
detection of Mmp8.
Tumor growth and lung metastasis
Tumor growth was assessed by biweekly palpations of
all 10 mammary glands from day 21 to day 98. Tumor
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to 1 cm, >1 cm. Tumor onset was recorded as the first
day when tumors could be detected by palpation.
At 14 weeks of age, mice were sacrificed and lungs
were injected intratracheally with 15% India ink. Lungs
were excised, washed in Carnoy’s fix and surface metas-
tases were imaged and counted using a Lumar Stereo-
scope (Carl Zeiss, Jena, Germany).
Quantitative real-time RT-PCR
Snap-frozen tumor tissue was homogenized in RNA-Bee
(Amsbio, Rockville, MD, USA) using a tissueLyser at
50Hz for 2 to 3 min and 7 mm stainless steel balls. RNA
was isolated from the homogenized tissue using a chloro-
form extraction method followed by a column purification
step (Promega, Madison, WI, USA). RNA quantity and
purity was assessed by A260/A280 and A260/A230
absorbance ratios using a Nanodrop system (Thermo
Fisher Scientific, Frederick, MD, USA). Reverse transcription
of 1 μg was performed using MMLV-Superscript (Sigma-
Aldrich, St Louis, MO, USA) resulting in a final concentra-
tion of 50 ng/μl. Quantitative real-time polymerase chain
reaction (qRT-PCR) was conducted using 5 ng cDNA for all
genes of interest and 1 ng cDNA for 18S rRNA and the
cycle conditions were as following: 2 min at 50°C, 10 min at
95°C, followed by 40 cycles of 15 sec at 90°C and 1 min at
60°C. Expression of IL-6, CXCL5 and CD68 was quantified
using specific 5′FAM-3′TAMRA Taqman gene expression
primer/probe sets (Mm00446190_m1, Mm00436451_g1,
Mm03047340_m1, Life Technologies, Carlsbad, CA, USA).
Expression levels were normalized to 18S rRNA using
forward primer 5′-GCCGCTAGAGGTGAAATTCTTG-3′,
reverse primer 5′-CATTCTTGGCAAATGCTTTC G-3′
and probe 5′-FAM-ACCGGCGCAAGACGGA-TAMRA-
3′. Specific primers and 5′FAM-TAMRA-3′ probes were
designed for all MMPs and tissue inhibitor of metallopro-
teinases (TIMPs), and synthesized by Sigma-Aldrich (Sigma-
Aldrich, St Louis, MO, USA). The sequences for the primers
and probes are given in Table 1.
Western blotting
Snap-frozen tumor tissue was homogenized in RIPA lysis
buffer (500 mM NaCl, 1% Triton-X100, 0.1% sodium
dodecylsulphate, 50 mM Tris pH 7.4) with complete
EDTA-free protease inhibitor cocktail mix (Roche Applied
Science, Penzberg, Germany) using a tissueLyser at
50Hz for 2 to 3 min and 7 mm stainless steel balls. Tis-
sue lysates were centrifuged for 10 min at 10,000 rpm,
supernatants were harvested and protein content was de-
termined using a BCA protein assay (Thermo Fisher Sci-
entific, Frederick, MD, USA). Tumor lysates were reduced
and denatured in Laemmli sample buffer (containing 4%
b2-mercaptoethanol) and equal amounts of total protein
were loaded onto a 10% SDS-PAGE gel. Proteins weretransferred onto polyvinylidene fluoride membrane (EMD
Millipore, Billerica, MA, USA), blocked in Tris-buffered
saline (TBS)/0.1% Tween-20/2.5% non-fat dried milk and
incubated overnight at 4°C with sheep anti-mouse MMP-
3 (the kind gift of Dr G. Murphy [25]) or mouse heat
shock protein-70 (sc-7298, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), diluted in TBS/ 0.1% Tween-20/
2.5% non-fat dried milk. The next day the membranes
were washed three times with TBS/0.1% Tween-20 for
5 min and incubated in horseradish peroxidase (HRP)-la-
beled secondary antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) for 1 hr. Finally, the
membranes were washed with TBS and imaged using ECL
chemiluminescence (Thermo Fisher Scientific, Frederick,
MD, USA) and Fujifilm LAS-3000 Imager (FujiFilm,
Tokyo, Japan). Densitometry was performed using Fiji
software [26].
Gelatin zymography
Tumor lysates were harvested and processed as for western
blotting, with the omission of protease inhibitors in the
lysis buffer. The samples were diluted in non-reducing
Laemmli sample buffer and loaded in equal amounts on a
7% gelatin-PAGE gel. Following electrophoresis, the gels
were washed twice with 2.5% Triton-X100 for 15 min,
briefly rinsed in water, followed by incubation in assay buf-
fer (100 mM Tris, 30 mM CaCl2, 0.02% NaN3) at 37°C
overnight. The next day the gel was stained in 0.25%
Coomassie Brilliant Blue G250 and destained using
30% methanol/1% acetic acid until clear bands of enzymatic
activity were visible. Imaging and quantification were per-
formed using the Licor Odyssey (Licor, Lincoln, NE, USA).
Immunofluorescence
Tumor tissue was harvested in 4% paraformaldehyde over-
night, paraffin-embedded and sectioned at 6 μm. Detection
of macrophages and neutrophils was achieved after trypsin
antigen retrieval using a primary antibody targeted against
respectively F4/80 clone Cl:A3-1 (MCA497R, AbD Serotec,
Kidlington, UK) and Ly6B2 clone7/4 (MCA771G, AbD
Serotec, Kidlington, UK) at a dilution of 1:100 in phosphate-
buffered saline (PBS)/0.1% Tween. Blood vessels were
detected using an antibody against Endomucin clone
V.7C7 (sc-65495, Santa Cruz Biotechnology, Dallas, TX,
USA) at a dilution of 1:500 in PBS/0.1% Tween-20.
Unspecific binding of primary antibody was prevented
by blocking the sections in PBS/0.1% Tween-20 with
10% normal donkey serum. Visualization was obtained
using a donkey-anti-rat Alexa594-labeled secondary anti-
body at 1:500 dilution in PBS/0.1% Tween-20. Sections
were mounted using Prolong Gold Antifade with DAPI
solution (Invitrogen, Carlsbad, CA, USA). The whole
section on a slide was imaged at 10x magnification using
automated slide scanning and the Zeiss Axiovision plugin
Table 1 Mmp and Timp primers and probe sequences
Forward primer (5′-3′) Reverse primer (5′-3′) Probe (5′-FAM, TAMRA-3′)
Timp 1 CATGGAAAGCCTCTGTGGATATG AAGCTGCAGGCACTGATGTG CTCATCACGGGCCGCCTAAGGAAC
Timp 2 CCAGAAGAAGAGCCTGAACCA GTCCATCCAGAGGCACTCATC ACTCGCTGTCCCATGATCCCTTGC
Timp 3 GGCCTCAATTACCGCTACCA CTGATAGCCAGGGTACCCAAAA TGCTACTACTTGCCTTGTTTTGTGACCTCCA
Timp 4 TGCAGAGGGAGAGCCTGAA GGTACATGGCACTGCATAGCA CCACCAGAACTGTGGCTGCCAAATC
ColA CGTGGACCAACAGCAGTGAA GAGTGAGCCCAAGGGAGTGA TCAACTTGTTCTATGTTACGGCTCATGAACTGG
ColB TGGACCGACAACAATGAGGAT TGGGAGAGTCCAAGGGAGTG TCAACTTGTTCTATGTTACGGCTCATGAACTGG
MMP-2 AACTACGATGATGACCGGAAGTG TGGCATGGCCGAACTCA TCTGTCCTGACCAAGGATATAGCCTATTCCTCG′
MMP-3 GGAAATCAGTTCTGGGCTATACGA TAGAAATGGCAGCATCGATCTTC AGGTTATCCTAAAAGCATTCACACCCTGGGTCT
MMP-7 GCAGAATACTCACTAATGCCAAACA CCGAGGTAAGTCTGAAGTATAGGATACA CCAAAATGGCATTCCAGAATTGTCACCTAC
MMP-8 GATTCAGAAGAAACGTGGACTCAA CATCAAGGCACCAGGATCAGT CATGAATTTGGACATTCTTTGGGACTCTCTCAC
MMP-9 CGAACTTCGACACTGACAAGAAGT GCACGCTGGAATGATCTAAGC TCTGTCCAGACCAAGGGTACAGCCTGTTC
MMP-10 CCTGCTTTGTCCTTTGATTCAGT CGGGATTCCAATGGGATCT TCCTATTCTTTAAAGACAGGTACTTCTGGCGCA
MMP-11 ATTGATGCTGCCTTCCAGGAT GGGCGAGGAAAGCCTTCTAG TCCTTCGTGGCCATCTCTACTGGAAGTTTG
MMP-12 GAAACCCCCATCCTTGACAA TTCCACCAGAAGAACCAGTCTTTAA AGTCCACCATCAACTTTCTGTCACCAAAGC
MMP-13 GGGCTCTGAATGGTTATGACATTC AGCGCTCAGTCTCTTCACCTCTT AAGGTTATCCCAGAAAAATATCTGACCTGGGATTC
MMP-14 AGGAGACAGAGGTGATCATCATTG GTCCCATGGCGTCTGAAGA CCTGCCGGTACTACTGCTGCTCCTG
MMP-15 ATCCCCTATGACCGCATTGAC CCCCTGCCAGACACTGATG ACACAGCATGGAGACCCTGGCTACCC
MMP-16 GGCTACCTTCCACCGACTGA CTTCATCCAGTCGATTGTGTTTCT CTGCAGAGACCATGCAGTCAGCTCTAGCT
MMP-17 GGCAGTATGTTCCTGCACTTCA GCTAGCACTGCCCTCAGGAT CCTGTGGACCTCAGTCTCTGCCAAGG
MMP-19 GCCCATTTCCGGTCAGATG AGGGATCCTCCAGACCACAAC CCACAAGGGCCCGTATGAAGCAGC
MMP-20 GATCAGGAGGATTAAGGAGCTACAAA GGCGGTAGTTAGCCACATCAG CCAGAATACAATGAATGTGATCAAGAAGCCTCG
MMP-21 TCCAAAGAAGATGAGCCAAGTG ACGCTGAATCGAGGTTTCTG TTCCAGCAATAATGCCTCAAAACCACCC
MMP-23 CAGACTGTTGACCATGTCGGTAA GAAGGAAAGAACTCTGTATGTGAGGTT CCGCTACACGCTGACACCGGC
MMP-24 TATCATGGCTCCCTTCTACCAATAC CTGCGGACCGGGAGTGT CCAGCTGAGCCCTCTGGAGCCA
MMP-25 TGGCTGTCTGGGCTACTGAA GGTAGGCCCGAGCAAAGTG AATTCTCAGTACCAGGAGCCTGACATCATTATCC
MMP-27 AGGATAATAAAGTGCTTCCCAGGA AAGAAATAGAGGAATCCATTATGTTGG TCGCCTCCGTGTGGATGCTGTC
MMP-28 CCACTTGGACAGAGAGGATCAGT AAGCGTTTCTTACGCCTCATTT CTGCTTGCTGGACACCGAGCCAA
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
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together, followed by image processing in Fiji and analysis
on Volocity.
Statistics
Data were analyzed using the two-tailed unpaired t test or
the chi-square test and are represented as mean ± standard
error of the mean (SEM) unless stated otherwise.
Results
Accelerated tumor onset and progression in
MMP-8-deficient PyMT mice
The effect of MMP-8 ablation on tumor onset and growth
was investigated in cohorts of Mmp8-wild-type, heterozy-
gote and null female PyMT littermates [27]. All 10 mam-
mary glands were palpated biweekly for the presence of
tumors. In MMTV-PyMT; Mmp8-null mice (KO; n = 10),
tumors were first detected at the age of 25 days comparedto 32 days in wild-type (WT; n = 17, P <0.01) and hetero-
zygote mice (HET; n = 30, P <0.05) (Figure 1A). All
MMTV-PyMT; Mmp8-null mice (n = 21) were tumor-
bearing at the age of 40 days, whereas full penetrance in
heterozygote (n = 34) and wild-type (n = 26) mice was not
observed until 50 and 55 days respectively (Figure 1B). No
difference in tumor multiplicity was found (data not
shown).
Tumor progression was assessed by biweekly palpation
from day 21 to day 98 and tumors were categorized accord-
ing to their size (0, <0.5, 0.5 to 1, >1 cm) as presented in
Figure 1C. At 10 weeks of age, MMTV-PyMT; Mmp8-wild-
type (n = 26) and heterozygote (n = 34) mice showed similar
tumor size distribution patterns with the majority of tumors
being between 0.5 to 1 cm. The Mmp8-null mice (n = 21)
overall presented with bigger tumors, with a remarkable
doubling of very large tumors (>1 cm, P <0.01) compared
to their wild-type or heterozygous littermates. At 14 weeks
Figure 1 Loss of MMP-8 accelerates tumor onset; promotes progression, tumor size and lung macrometastases in the MMTV-PyMT model.
(A) Detection of first palpable tumors of MMTV-PyMT; Mmp8-wild-type (WT, n = 17), MMTV-PyMT; Mmp8-heterozygote (HET, n = 30) and MMTV-PyMT;
Mmp8-null (KO, n = 10) mice. Mean ± SEM, two-tailed unpaired t test; *P <0.05; **P <0.01. (B) Tumor progression determined by palpation of all 10
mammary glands from day 21 to day 98 for MMTV-PyMT; Mmp8-wild-type (WT, n = 26), −heterozygote (HET, n = 34) and -null (KO, n = 21) mice. (C)
Tumor size distribution (0, <0.5, 0.5 to 1, >1 cm) at 10 weeks of age for MMTV-PyMT; Mmp8-wild-type (WT, n = 26), MMTV-PyMT; Mmp8-heterozygote
(HET, n = 34) and MMTV-PyMT; Mmp8-null (KO, n = 21) mice; and at 14 weeks of age for MMTV-PyMT; Mmp8-wild-type (WT, n = 22), MMTV-PyMT; Mmp8-
heterozygote (HET, n = 30) and MMTV-PyMT; Mmp8-null (KO, n = 16) mice. chi-square test, *P <0.01. (D) Number of lung macrometastases assessed at
14 weeks of age for MMTV-PyMT; Mmp8-wild-type (WT, n = 4), MMTV-PyMT; Mmp8-heterozygote (HET, n = 4) and MMTV-PyMT; Mmp8-null (KO, n = 2)
mice. Left panel of representative pictures depicts the top and bottom of all lung lobes (one lobe of the left lung, four lobes of the right lung).
Black solid arrows = smaller macrometastases, white solid arrows = larger macrometastases. Mean ± SEM, two-tailed unpaired t test; **P <0.01. MMP, matrix
metalloproteinase; MMTV, mouse mammary tumor virus; PyMT, Polyoma virus middle T-antigen; SEM, standard error of the mean.
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between wild-type (n = 22) and heterozygote (n = 30) mice
with the majority of tumors being larger than 1 cm. In line
with the observations at 10 weeks, Mmp8-null mice (n = 16)
had a significantly greater proportion of very large tumors
(P <0.01).Induction of lung surface metastases in MMP-8-deficient
PyMT mice
PyMT transgenic mice are prone to the formation of lung
metastases so we assessed the impact of MMP-8 defi-
ciency on the spread of the disease to this site (Figure 1D)
[27]. At 14 weeks of age, 100% of female PyMT mice had
lung metastases. Although on a limited cohort, Mmp8-
null PyMT mice had a significant 11.8-fold increase in the
number of lung surface metastases (520 ± 55) compared
to wild-type or heterozygote PyMT mice (44 ± 5).Changes in angiogenesis in MMP-8-deficient PyMT mice
Changes in blood vessel formation were investigated by
immunohistochemical analysis of endomucin at different
time points (Figure 2) [28]. Endomucin staining was
high in tumors in all of the genotypes at 8 weeks. In
contrast, at 10 weeks of age there was a significant drop
(P <0.04) in vascularity in MMTV-PyMT; Mmp8-wild-
type tumors compared to those in Mmp8-heterozygoteWT
Blood vessels
Endomucin
10weeks
Figure 2 Altered MMTV-PyMT tumor vascularity in Mmp8-null mice. V
by Endomucin staining. The number of mice used for analyses were as foll
Mmp8 heterozygote (HET, n = 5), MMTV-PyMT; Mmp8 null (KO, n = 5), and 1
heterozygote (HET, n = 6) and MMTV-PyMT; Mmp8 null (KO, n = 4). Represen
matrix metalloproteinase; MMTV, mouse mammary tumor virus; PyMT, Polyor -null animals, which remained at the higher levels
seen at the 8-week stage.
Changes in immune cell infiltrates and proinflammatory
mediators in MMP-8-deficient PyMT mice
We investigated the effect of MMP-8 deficiency on macro-
phage and neutrophil cell infiltrates during disease progres-
sion using F4/80 and Ly6B2 for immunohistochemistry
analysis and CD68 for RNA profiling [29]. No substantial
or significant difference in the number of macrophages
was found between the various Mmp8 genotypes through-
out the time course of disease (Figure 3). Though image
quantification showed an apparently statistically significant
increased level of macrophage staining at 6 weeks in
Mmp8-null mice, this was based on only two Mmp8-null
mice and should be interpreted with caution. Macrophage
staining in all genotypes peaked at 8 weeks, which is also
reflected in CD68 mRNA levels. On the other hand, expres-
sion of the proinflammatory mediators IL-6 and the murine
IL-8 ortholog CXCL-5/LIX rose from early- (6 weeks) to
later-stage disease (10 to 14 weeks) and were generally
somewhat higher in MMP-8-deficient animals (both
Mmp8-heterozyote and -null) than wild-type (Figure 3B).
Looking at neutrophil infiltration, no significant differ-
ences were apparent between genotypes at early time
points (Figure 3A). However, at 10 weeks significantly
lower numbers of neutrophils were observed in tumorsHET KO
ascular density of tumors in early- and late-stage tumors as determined
owing: 8 weeks; MMTV-PyMT; Mmp8 wild-type (WT, n = 4), MMTV-PyMT;
0 weeks; MMTV-PyMT; Mmp8 wild-type (WT, n = 4), MMTV-PyMT; Mmp8
tative pictures of 10-week tumors are shown.*P <0.05, **P <0.01. MMP,
oma virus middle T-antigen.
A) WT HET KO
Macrophages 
F4/80 
10 weeks 
Neutrophils 
Ly6B.2 
10 weeks 
B) 
Figure 3 Loss of MMP-8 affects MMTV-PyMT neutrophil, but not macrophage, infiltration and expression of proinflammatory
mediators. (A) Number of macrophages/mm2 and neutrophils/mm2 in early- and late-stage tumors as determined by staining for F4/80 and Ly6B.2,
respectively. The number of mice used for analyses of macrophage and neutrophil infiltration respectively were at 6 weeks: Mmp8 wild-type (WT, n = 5,
5), heterozygote (HET, n = 4, 3) and null (KO, n = 2, 3); 8 weeks: Mmp8 wild-type (WT, n = 4, 5), heterozygote (HET, n = 6, 5), null (KO, n = 4, 5) and at
10 weeks: Mmp8 wild-type (WT, n = 5, 5), heterozygote (HET, n = 5, 5) and null (KO, n = 4, 4).*P <0.05, **P <0.01. One representative image of macrophage
and neutrophil staining is shown for each genotype at 10 weeks of age. (B) Relative RNA expression of macrophage marker CD68, IL-6 and CXCL5/LIX,
normalized to 18S rRNA, throughout disease progression (6 to 14 weeks of age). IL, interleukin; MMP, matrix metalloproteinase; MMTV, mouse mammary
tumor virus; PyMT, Polyoma virus middle T-antigen.
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and Mmp8-null mice (P = 0.02).
Perturbation of the MMP and TIMP families in
MMP-8-deficient PyMT mice
The consequences of MMP-8 ablation on the protease web
were assessed through a comprehensive real-time qRT-
PCR profiling of the MMP and TIMP families (Figure 4A)
in end-stage (14 week) tumors [30]. The highest overall ex-
pression levels were shown by Mmp15 and Timp2, with
several genes showing very low expression in tumors (in-
cluding Mcol-a/b, Mmp7, Mmp10, Mmp20 and Timp4). A
more in-depth RNA analysis in the form of a time-course
profile (6 to 8 to 10 to 14 weeks; Figure 4C) was performed
for all MMPs/TIMPs with a significant 50% change
(+1.5- or −2.0-fold change) in Mmp8-null mice com-
pared to wild-type mice (shaded grey in Figure 4B).
Due to the very low expression levels of Mcol-a and Mcol-
b, further analysis was not pursued. Several genes showed
progressive increases during tumor growth, including
Mmp2, Mmp3, Mmp13 and Mmp16, whereas Timp2
and Mmp27 showed more dynamic fluctuations in ex-
pression. Protein expression of a select number of can-
didate altered genes (MMP-3, MMP-13, TIMP-2) was
performed based on the availability of antibodies for
western blot analysis. While the changes observed at
the RNA level could not be confirmed at the protein level
for MMP-13 and TIMP-2 (data not shown), the decrease
in MMP-3 expression in Mmp8-null mice was clearly ap-
parent (Figure 5A). Zymography analysis of tumor homog-
enates showed no changes in overall expression levels of
the gelatinases MMP-2 and MMP-9, though there was a
slight reduction in the ratio of active MMP-2/pro-MMP-2
in heterozygote and null mice compared to their wild-type
littermates at end-stage disease or 14 weeks of age
(Figure 5B).
Discussion
Matrix metalloproteinase-8 has emerged as a key tumor-
suppressive enzyme and thus an anti-target for MMP-
directed therapies [4,31,32]. The current study provides the
first evidence from a spontaneous mouse tumor model for
the tumor- and metastasis-suppressive functions of MMP-8.
Despite the already aggressive nature of the MMTV-PyMT
model, which leads to rapid, multifocal tumor formation in
the mammary gland and a high frequency of lung metastasis
[22,33], homozygous loss of MMP-8 further accelerated
tumor onset, progression and lung surface metastasis forma-
tion. In the later stages of tumor development (10 weeks of
age), we found that while vascularization and neutrophil in-
filtration in tumors in wild-type animals had decreased over-
all compared to earlier lesions at 8 weeks, these parameters
remained elevated in MMP-8 deficient animals. Moreover,
loss of MMP-8 led to changes in the expression or activationof other MMPs, particularly MMP-3. Thus, the absence of
MMP-8 has multiple consequences for angiogenesis, innate
immune responses and metastasis that conspire to promote
tumor growth and malignancy, and which may involve sys-
temic disturbance of the protease web.
Our observations in the MMTV-PyMT mouse mam-
mary cancer model concur with observations of a sup-
pressive role for host-derived MMP-8 in carcinogen-
induced skin tumorigenesis. Male Mmp8-null mice have
been shown to have enhanced formation of skin papillo-
mas, which could be rescued by transfer of bone marrow
from wild-type mice, suggesting that neutrophils (as the
main source of MMP-8) are protective in the early stages
of lesion formation [13]. A similar protective role for host
neutrophil-derived MMP-8 was observed in spontaneous
and experimental metastasis experiments with syngeneic
Lewis lung carcinoma and B16F10 melanoma cells in
C57Bl6 Mmp8-null mice [9]. However, tumor cell-expressed
MMP-8 is also suppressive, so it is likely that the presence
of MMP-8 in the tumor microenvironment, rather than its
source, is the critical factor [9,15,16,34]. Expression of
MMP-8 by tumor cells reduces invasion and increases adhe-
sion to type-I collagen and laminin matrices [9]. Interest-
ingly, an RNA interference screen has identified MMP-8 as
a protein that interacts with and modifies the activity of β1
integrin, which may be the basis for its effects on tumor cell
adhesion [35].
Although Mmp8-null mice have no overt phenotype
without challenge (and of particular relevance for the
present study we have seen no abnormalities in early
mammary gland morphogenesis by whole mount stain-
ing, data not shown), they show altered inflammatory
responses in several disease or pathology models, which
can result in either exacerbation or protection depending
on the context. In skin carcinogenesis or excisional wound
repair, Mmp8-null mice show delayed neutrophil recruit-
ment at early stages, but there is persistent neutrophil accu-
mulation at later times, leading to a chronic inflammatory
milieu that enhances tumor formation and impairs wound
repair [9,36]. This is also apparent in models of peri-
odontitis and lipopolysaccharide (LPS)-induced corneal
inflammation [37-39]. In all of these scenarios, the initial
recruitment of neutrophils is an important factor in or-
chestrating the inflammatory response to allow its subse-
quent resolution when the source of the inflammation is
eliminated or tissue damage is repaired. In the MMTV-
PyMT model we found no deficit in neutrophil accumula-
tion at early-mid stages of tumor development (6 and
8 weeks), but by 10 weeks the neutrophil count in sections
of wild-type tumors had declined, whereas levels remained
elevated for tumors in both Mmp8-null and -heterozygote
mice. The highly aggressive nature of the MMTV-
PyMT model may be linked with the intrinsically high level
of neutrophils in these tumors, similar to the previously
Figure 4 MMP-8 ablation perturbs the tumor protease web at the RNA level. (A) qRT-PCR profiling of MMP and TIMP RNA expression at
14 weeks of age with expression levels classified as very high (CT <25), high (CT = 26 to 30), moderate (CT = 31 to 35), low (CT = 36 to 39) or not detected
(CT = 39 to 40). (B) MMPs and TIMPs with a significant change in expression in PyMT knockout (KO) or heterozygote (HET) mice compared to wild-type
(WT) littermates at 14 weeks of age. Genes with significant 50% up- (FC +1.5) or down-regulated (FC −2.0) expression in null mice compared to wild-type
littermates are highlighted in grey. FC, fold change. (C) RNA time course of selected MMPs and TIMPs (highlighted in grey in Figure 4B). Expression data
was normalized to 18S rRNA, throughout disease progression (6 to 14 weeks of age) and expressed as arbitrary units. MMP, matrix metalloproteinase;
PyMT, Polyoma virus middle T-antigen; qRT-PCR, quantitative real-time polymerase chain reaction; TIMP, tissue inhibitor of metalloproteinases.
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tential of these transgenic mice and macrophage infiltra-
tion [40,41]. Reflecting this, F4/80-positive macrophageinfiltration was unaffected by Mmp8 genotype throughout
lesion development and progression. However, the ab-
sence of MMP-8 led to persistence of neutrophils in
Figure 5 MMP-8 ablation perturbs the tumor protease web at the protein level. (A) MMP-3 protein expression in tumor tissue at 14 weeks
of age as determined by western blotting. Quantification of three biological replicates per genotype, normalized to Hsc70 and compared to PyMT
wild-type (WT). Two-tailed unpaired t test, mean ± SEM. (B) Tumor expression of MMP-2 and MMP-9 forms by gelatin zymography at 10 and 14 weeks
of age. two-tailed unpaired t test; AU, arbitrary unit; FC, fold change; MMP, matrix metalloproteinase; ns, non-significant; PyMT, Polyoma virus middle
T-antigen; SEM, standard error of the mean.
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tumor development. Along with the sustained high neutro-
phils levels in Mmp8-null mice, we observed that vascular
density in 10-week tumors remained at the high levels seen
in 8-week lesions, while it decreased in tumors in wild-
type mice. This reduced angiogenesis in wild-type tumors
is surprising given that the tumors are still growing up to
the end point of the model. However, there is widespread
necrosis at later stages of tumor growth (from 10 weeks
onwards), potentially as a result of growth outstripping
vascularization. Since we quantify all vessels across theentire tumor section, and not only the vessels near the pro-
liferative margins, the increase in necrotic area likely con-
tributes to the decreased vascular density observed in wild-
type tumors at 10 weeks compared to the 8-week time
point. Both neutrophil accumulation and vascular density
may contribute directly to the enhanced growth and me-
tastatic spread of tumors that we have observed in the
Mmp8-null mice. Indeed the reduction in tumor-associated
neutrophils in tumors in wild-type mice could be directly
responsible for the diminished vascular density due to re-
duced release of pro-angiogenic factors [42-46]. However,
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phenotype’ or the pro-tumorigenic ‘N2’ variety, with TGF-
β directing the accumulation of the latter [47], it will be
important to investigate further the nature of the neutro-
phils present in tumors in wild-type mice versus those in
Mmp8-null and heterozygotes. This is particularly relevant
given the recent links between MMP-8 and inhibition of
TGF-β signaling [15,19]. It is also important to note that
we found evidence of a sustained inflammatory milieu in
lesions in Mmp8-null and Mmp8-heterozygote mice,
resulting in higher expression of proinflammatory me-
diators IL-6 and LIX/CXCL-5 at the end stage of the
MMTV-PyMT model, which may also contribute to en-
hanced malignant potential.
It had been previously thought that the key driver for
the role of MMP-8 in neutrophil migration was its ability
to cleave and activate the chemokine IL-8 or its murine
counterpart LIX/CXCL-5 [17]. Cleavage of IL-8/LIX by
MMP-8 released from neutrophils was argued to provide
a feed-forward mechanism to drive rapid initial neutrophil
recruitment, with loss of MMP-8 leading to impaired neu-
trophil migration. However, recent studies indicate that
the in vivo inflammatory phenotypes resulting from loss
of MMP-8 are indirect, and relate to its long-recognized
ability to cleave and inactivate the abundant plasma serine
protease inhibitor, α1-proteinase inhibitor (α1-PI), which
regulates the activity of neutrophil elastase [48,49]. Thus,
neutrophil elastase activates IL-8/LIX, and its activity is
influenced by MMP-8 via α1-PI [49]. This is an example
of the interconnectedness of the ‘protease web’, whereby
the consequences of in vivo genetic inactivation of a par-
ticular proteolytic enzyme can have major repercussions
for the activities or expression of other proteases, includ-
ing other protease classes operating in distant tissue loca-
tions [50]. We have seen evidence of this from profiling
the expression of the entire MMP and TIMP families in
the MMTV-PyMT tumors in Mmp8-null mice, where we
observed altered expression of Mmp2, 3, 13, 16, 27 and
Timp2 transcripts, and we confirmed reduced expression
of MMP-3 at the protein level. The reduction in MMP-3
expression may itself contribute to the enhanced tumor
and metastatic capability of MMTV-PyMT tumors in
the Mmp8-null background. Transgenic mice overex-
pressing MMP-3 in their mammary glands show reduced
carcinogen-induced mammary tumors as a result of in-
creased epithelial cell apoptosis [51]. A protective role for
MMP-3 has also been seen in skin squamous cell carcin-
oma [52]. The increased expression of Timp2 transcripts
that we observed in tumors of Mmp8-null mice might also
contribute to localized effects on MT1-MMP-mediated
activation of pro-MMP-2, leading to enhanced invasion
and metastasis. It is likely that such changes in the protease
web may also contribute to the different vascularization of
tumors in Mmp8-wild-type, −heterozygote and -null mice.With the recent link that has been forged between MMP-
8 and miR-21 [15], and recognition of the impact of
microRNAs on the expression of several key degradome
players, for example MMP-3, MMP-13 and TIMP-2, the
effects of MMP-8 ablation on miRNA expression might
be an interesting avenue for future research [53-61].
Conclusions
This study demonstrates that the suppressive effects of
MMP-8 on tumorigenesis and metastasis are apparent
even in an aggressive spontaneous model of mammary car-
cinoma, and that loss of MMP-8 function has pleiotropic
effects on angiogenesis and inflammatory cell involvement,
accompanied by changes within proteolytic networks oper-
ating within tumors.
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